Просто «таблетка». Шестьдесят лет открытий и достижений, которые изменили мир. Часть I. гормональная контрацепция: от идеи к совершенству


DOI: https://dx.doi.org/10.18565/pharmateca.2020.6.10-17

Г.Б. Дикке

Академия медицинского образования им. Ф.И. Иноземцева, Санкт-Петербург, Россия
Настоящий обзор литературы представляет собой очерк истории развития гормональной контрацепции со времени появления идеи предупреждения беременности и далее на протяжении 60 лет от выпуска первой контрацептивной «таблетки» до наших дней.
Ключевые слова: предупреждение беременности, контрацепция, гормональные контрацептивы

Литература


1. Феррис П. Зигмунд Фрейд. Пер. с англ. Е. Мартинкевич. Мн.: Попурри. 2001. 448 с.


2. Сакевич В.И. 60 лет Международной Федерации планируемого родительства. Демоскоп Weekly. 2012;531–32


3. Sanger M. Morality and Birth Control. Birth Control Review. 1918 February-March: 11–4. https://ru.citaty.net.


4. Henderson J. A Life of Ernest Starling. Oxford University Press. 2005. 229 р.


5. Weintraub B. Pincus, Djerassi and Oral Contraceptives. Chemistry in Israel. Bulletin of the Israel Chemical Society. August 2005.


6. Pletzer B.A., Kerschbaum H.H. 50 years of hormonal contraception-time to find out, what it does to our brain. Front Neurosci. 2014;8:256. Doi:10.3389/fnins.2014.00256.


7. Casey C.L., Murray C.A. HT update: spotlight on estradiol/norethindrone acetate combination therapy. Clin Interv Aging. 2008;3(1):9–16. Doi:10.2147/cia.s1663.


8. Liao P.V., Dollin J. Half a century of the oral contraceptive pill: historical review and view to the future. Can Fam Physician. 2012;58(12):e757–60.


9. Gibbs N. Time Executive Editor. Time Magazine, May 3, 2010.


10. Демографическая модернизация России 1900–2000. Под ред. А.В. Вишневского. М., 2006. 608 с.


11. Marrs С., Gomer К. Nelson Pill Hearings Annotated. Research. Lucine Health Sciences, INC. 2016. Р. 5921–6445. Doi: 10.13140/RG.2.2.32749.64489.


12. Rabe T., Luxembourg B., Ludwig M., et al. Contraception and Thrombophilia – A statement from the German Society for Gynecological Endocrinology and Reproductive Medicine (DGGEF e.V.) and the Professional Association of German Gynaecologists (BVF e.V.). J Reprodukt Endokrinol. 2011;8(Special Issue 1):178–218.


13. Burkman R., Bell C., Serfaty D. The evolution of combined oral contraception: improving the risk-to-benefit ratio. Contraception. 2011;84(1):19–34.


14. Chernick B.A. Side effects of cyclic therapy with norethindrone and mestranol. Fertil Steril. 1965;16(4):445–54.


15. Schindler A.E., Campagnoli C., Druckmann R.,et al. Classification and pharmacology of progestins. Maturitas. 2008;61(1):171–80.


16. Rice-Wray E., Avila C., Gutiérrez J. Norgestrel and ethynyl estradiol: a new low-dosage oral agent for fertility control. Obstet Gynecol. 1968;31(3):368–74.


17. Ismail M.T. A randomised comparative study of Triquilar versus Marvelon: the Malaysian experience. Malays J Reprod Health.1991;9(1):9–17.


18. Zador G., Nilsson B.A., Nilsson B., et al. Clinical experience with the uterine progesterone system (Progestasert R). Contraception. 1976;13(5):559–69.


19. Nelson A.L., Massoudi N. New developments in intrauterine device use: focus on the US. Open Access. J Contracept. 2016;7:127–41. Doi: 10.2147/OAJC.S85755


20. Fotherby K., Trayner I., Longthorne P.N., et al. Metabolic investigations with Femodene –an oral contraceptive containing gestodene and ethinyloestradiol. Contraception. 1987;35(4):323–37.


21. Bringer J. Norgestimate: a clinical overview of a new progestin. Am J Obstet Gynecol. 1992;166(6 Pt. 2):1969–77.


22. Etonogestrel. Drugs and Lactation Database (LactMed)


23. Ruan X., Seeger H., Mueck A.O. The pharmacology of dienogest. Maturitas. 2012;71(4):337–44. Doi: 10.1016/j.maturitas.2012.01.018.


24. Rapkin A.J., Sorger S.N., Winer S.A. Drospirenone/ethinyl estradiol. Drugs Today (Barc). 2008;44(2):133–45. Doi: 10.1358/dot.2008.44.2.1191057.


25. Mueck A.O., Sitruk-Ware R. Nomegestrol acetate, a novel progestogen for oral contraception. Steroids. 2011;76(6):531–39. Doi: 10.1016/j.steroids.


26. Lidegaard Ø., Løkkegaard E., Svendsen A.L., Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009;339:b2890.


27. Parke S., Junge W., Mellinger U., et al. Oral Comparative effects of a four-phasic regimen of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel on haemostatic parameters. Hum Reprod. 2008;23(Suppl. 1):i77–i78.


28. Ågren U.M., Anttila M., Mäenpää-Liukko K., et al. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism. Eur J Contracept Reprod Health Care. 2011;16:444–57.


29. Zeun S., Lu M., Uddin A., et al. Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care. 2009;14(3):221–32.


30. Agren U.M., Anttila M., Mäenpää-Liukko K., et al. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism. Eur J Contracept Reprod Health Care. 2011;16(6):444–57.


31. Jensen J.T. Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest. Expert Opin Pharmacother. 2010;11(7):1147–57.


32. Duijkers I.J., Klipping C., Grob P., et al. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17 beta-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol. Eur J Contracept Reprod Health Care. 2010;15(5):314–25.


33. Mansour D., Verhoeven C., Sommer W., et al. Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. Eur J Contracept Reprod Health Care. 2011;16(6):430–43.


34. Westhoff C., Kaunitz A.M., Korver T., et al. Efficacy, safety, and tolerability of a monophasic oral contraceptive containing nomegestrol acetate and 17β-estradiol: a ran-domized controlled trial. Obstet Gynecol. 2012;119(5):989–99.


35. Dinger J., Do Minh T., Heinemann K. Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception. 2016;94(4):328–39. Doi: 0.1016/j.contraception.2016.06.010.


36. Graziottin A. The shorter, the better: A review of the evidence for a shorter contraceptive hormone-free interval. Eur J Contracept Reprod Health Care. 2016;21(2):93–105. Doi: 10.3109/13625187.2015.1077380.


37. Grandi G., Xholli A., Napolitano A., et al. Prospective measurement of blood pressure and heart rate over 24 h in women using combined oral contraceptives with estradiol. Contraception. 2014;90(5):529–34. Doi: 10.1016/j.contraception.2014.05.011.


38. Burness C.B. Extended-Cycle Levonorgestrel/Ethinylestradiol and Low-Dose Ethinylestradiol (Seasonique): A Review of Its Use as an Oral Contraceptive. Drugs. 2015;75(9):1019–26. Doi: 10.1007/s40265-015-0407-9.


39. Nau J.Y. Lybrel and menstrual cessation. Rev Med Suisse. 2007;3(110):1209.


40. Elliesen J., Trummer D. Adherence to a flexible extended regimen for oral hormonal contraception provided in blister packaging compared with an adherence-supporting digital tablet dispenser: historical comparison of data from two clinical studies. Int J Womens Health. 2016;8:351–56. Doi: 10.2147/IJWH.S107516.


41. Bennett J.P. The Second Generation of Hormonal Contraceptives. In: Chemical Contraception. Palgrave, London; 1974. Р. 39–62. Doi: 10.1007/978-1-349-02287-8_4.


42. Bruess C.E., Oswalt S.B. Exploring the Dimensions of Human Sexuality. Jones & Bartlett Publishers; 2016. 824 р.


43. French K. Sexual Health. John Wiley & Sons; 2009. Р. 92–3.


44. Lortscher D., Admani S., Satur N., Eichenfield L.F. Hormonal Contraceptives and Acne: A Retrospective Analysis of 2147 Patients. J Drugs Dermatol. 2016;15(6):670–74.


45. Ahrendt H.J., Makalová D., Parke S., Mellinger U., Mansour D. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception. 2009;80(5):436–44. Doi: 10.1016/j.contraception.2009.03.018.


46. Fraser I.S., Parke S., Mellinger U., et al. Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest. Eur J Contraception Reprod Health Care. 2011;16:258–69.


47. Kaunitz A.M., Bissonnette F., Monteiro I., et al. Levonorgestrel-releasing intrauterine system or medroxy-progesterone for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010;116(3):625–32.


48. Pearlstein T.B., Bachmann G.A., Zacur H.A., Yonkers K.A. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 2005;72(6):414–21.


49. Rapkin R.B., Creinin M.D. The combined oral contraceptive pill containing drospirenone and ethinyl estradiol plus levomefolate calcium. Expert Opin Pharmacother. 2011;12(15):2403–10. Doi: 10.1517/14656566.2011.610791.


50. Sitruk-Ware R., Nath A., Mishell D.R. Contraception technology: past, present and future. Contraception. 2013;87(3):319–30. Doi: 10.1016/j.contraception.2012.08.002.


Об авторах / Для корреспонденции


Автор для связи: Г.Б. Дикке, д.м.н., доцент, профессор кафедры акушерства и гинекологии с курсом репродуктивной медицины, 
Академия медицинского образования им. Ф.И. Иноземцева, Санкт-Петербург; тел. +7 (812) 334-76-50; e-mail: galadikke@yandex.ru; ORCID: https://orcid.org/0000-0001-9524-8962 
Адрес: 190013, Россия, Санкт-Петербург, Московский пр-т, 22, лит. М


Бионика Медиа